Randomized, double-blind, phase III clinical study of a novel nanotechnological topical anesthetic formulation containing lidocaine 25 mg/g and prilocaine 25 mg/g (nanorap) in skin phototypes I-III patients with ablative fractional CO2 laser treatment indication in the forehead.
Cíntia GobbatoAndré GobbatoTainah B MagalhãesGustavo D MendesJaime O IlhaRonilson A MorenoNatalícia de Jesus AntunesGilberto De NucciPublished in: Lasers in surgery and medicine (2019)
The nanorap formulation demonstrated a clinically and statistically significant efficacy providing analgesia after the ablative fractional CO2 laser therapy in the investigated patients, when compared to placebo. The product also presented good safety and tolerability. Lasers Surg. Med. © 2019 Wiley Periodicals, Inc.
Keyphrases
- double blind
- phase iii
- placebo controlled
- open label
- clinical trial
- phase ii
- end stage renal disease
- study protocol
- drug delivery
- ejection fraction
- newly diagnosed
- prognostic factors
- chronic kidney disease
- randomized controlled trial
- soft tissue
- peritoneal dialysis
- single molecule
- mass spectrometry
- botulinum toxin
- high speed
- atomic force microscopy
- high resolution